KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Ratio (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Equity Ratio for 17 consecutive years, with 0.8 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Equity Ratio fell 0.99% year-over-year to 0.8, compared with a TTM value of 0.8 through Dec 2025, down 0.99%, and an annual FY2025 reading of 0.8, down 0.99% over the prior year.
  • Equity Ratio was 0.8 for Q4 2025 at Biomarin Pharmaceutical, down from 0.81 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.81 in Q1 2025 and bottomed at 0.71 in Q4 2021.
  • Average Equity Ratio over 5 years is 0.75, with a median of 0.73 recorded in 2022.
  • The sharpest move saw Equity Ratio grew 17.66% in 2021, then decreased 0.99% in 2025.
  • Year by year, Equity Ratio stood at 0.71 in 2021, then increased by 1.64% to 0.72 in 2022, then rose by 0.23% to 0.72 in 2023, then increased by 11.86% to 0.81 in 2024, then dropped by 0.99% to 0.8 in 2025.
  • Business Quant data shows Equity Ratio for BMRN at 0.8 in Q4 2025, 0.81 in Q2 2025, and 0.81 in Q1 2025.